Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMUR2 | Q9GZQ4 | 5/20 | 0.56 |
| ▸ | NMUR1 | Q9HB89 | 5/20 | 0.56 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.55 |
| ▸ | NPY4R | P50391 | 8/20 | 0.55 |
| ▸ | NPY5R | Q15761 | 7/20 | 0.55 |
| ▸ | NPY1R | P25929 | 6/20 | 0.55 |
| ▸ | NPY2R | P49146 | 4/20 | 0.55 |
| ▸ | KDM1A | O60341 | 2/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29530519 | 0.87 | EPHA2 (0.50) | NMUR2NMUR1EPHA2NPY4RNPY5R | |
| SCHEMBL29972993 | 0.85 | NMUR2 (0.60) | NMUR2NMUR1NPY4RNPY5RNPY1R | |
| SCHEMBL29572169 | 0.84 | MAPK8 (0.59) | NPY4RNPY5RNPY1RNPY2RKDM1A | |
| SCHEMBL30389216 | 0.84 | EPHA2 (0.60) | NMUR2NMUR1EPHA2NPY4RNPY5R | |
| SCHEMBL29657984 | 0.84 | EPHA2 (0.57) | NMUR2NMUR1EPHA2NPY4RNPY5R | |
| SCHEMBL8876493 | 0.84 | NPY4R (0.60) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL31437202 | 0.83 | OPRM1 (0.46) | NMUR2NMUR1EPHA2KDM1A | |
| SCHEMBL3863996 | 0.82 | NMUR2 (0.56) | NMUR2NMUR1EPHA2KDM1A | |
| SCHEMBL3864010 | 0.82 | NMUR2 (0.56) | NMUR2NMUR1EPHA2KDM1A | |
| SCHEMBL30312779 | 0.82 | NTSR1 (0.72) | NPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | NORTHWESTERN UNIVERSITY (US) | 2022-03-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11261237-B2 | Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection | VEGFA, LITAF, FIBP | NMUR2 2265/4885NMUR1 1913/4885EPHA2 1487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.